Showing results (91-100 of 100) with videos related to
Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Injury|September 2, 2022
Risk factors for loss to follow up of pelvis and acetabular fracturesColin K Cantrell, Gregory H Versteeg, Cody J Goedderz, et al.Rejuvenation Research|January 28, 2014
Skeletal muscle mass, bone mineral density, and walking performance in masters cyclistsTakashi Abe, Vinayak K Nahar, Kaelin C Young, et al.The Journal of Arthroplasty|May 20, 2024
The Otto Aufranc Award: Does Hip Arthroscopy at the Time of Periacetabular Osteotomy Improve the Clinical Outcome for the Treatment of Hip Dysplasia? A Multicenter Randomized Clinical TrialPaul E Beaulé, Jeroen C F Verhaegen, John C Clohisy, et al.Schweizerische Medizinische Wochenschrift|October 26, 1996
Profile of CGP 61755: a novel and potent HIV-1 protease inhibitor that shows enhanced anti-HIV activity when combined with other antiretroviral agents in vitroJ K Lazdins, G Bold, H G Capraro, et al.Journal of Medicinal Chemistry|August 28, 1998
New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical developmentG Bold, A Fässler, H G Capraro, et al.Journal of Medicinal Chemistry|July 6, 2000
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesisG Bold, K H Altmann, J Frei, et al.Cancer Research|April 29, 2000
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administrationJ M Wood, G Bold, E Buchdunger, et al.Nature Biomedical Engineering|July 18, 2025
Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreadingSadeem Qdaisat, Brandon Wummer, Brian D Stover, et al.Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
mRNA aggregates harness danger response for potent cancer immunotherapyHector R Mendez-Gomez, Anna DeVries, Paul Castillo, et al.Cell|May 2, 2024
RNA aggregates harness the danger response for potent cancer immunotherapyHector R Mendez-Gomez, Anna DeVries, Paul Castillo, et al.Pageof 10